USPTO Art Unit 1612 Prosecution Statistics

Art Unit Information

Art Unit: 1612
Group: 1610
Tech Center: 1600
Total Cases: 13,765
Last Active: September 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19339250Intraoral Cleaning TabletSeptember 2025December 2025Allow300NoNo
19307939COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDAugust 2025October 2025Allow200NoNo
19209056STABLE PHARMACEUTICAL FORMULATIONS OF AMINO ACIDS, PEPTIDES OR PROTEINSMay 2025January 2026Allow810YesNo
19208234CHROMOPHORIC COMPOUNDS AND UV-ABSORBING COMPOSITIONSMay 2025August 2025Allow300NoNo
19194125ORGANIC NANOCOMPOSITE COATING FOR PHARMACEUTICAL APPLICATIONS AND A METHOD OF FABRICATION THEREOFApril 2025August 2025Allow301NoNo
19186092TREATMENT OF IMMUNOSUPPRESSED SUBJECTSApril 2025June 2025Allow210NoNo
19183794NEW TOPICAL FORMULATIONS OF RUXOLITINIB WITH AN ORGANIC AMINE PH ADJUSTING AGENT FOR TREATMENT OF SKIN DISEASESApril 2025October 2025Allow610NoNo
19177144Lip Balm Containing Caffeine, Nicotine or TestosteroneApril 2025December 2025Abandon820YesNo
19058911Methods of Preparing Dual-Indexed DNA Libraries for Bisulfite Conversion SequencingFebruary 2025August 2025Allow610NoNo
19045297SKIN BRIGHTENING COMPOSITIONS WITH THIOPYRIDINONE COMPOUNDFebruary 2025August 2025Allow710NoNo
19028294STABILIZED STANNOUS COMPOSITIONSJanuary 2025October 2025Allow900NoNo
19029372Orally Adhering Lozenges Containing Soluble Dietary FiberJanuary 2025October 2025Abandon911NoNo
19011752LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOFJanuary 2025October 2025Allow920NoNo
19011111STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEJanuary 2025November 2025Allow1010NoNo
19005154PHARMACEUTICAL FORMULATIONDecember 2024November 2025Allow1030NoNo
19001318STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEDecember 2024November 2025Allow1010NoNo
18986700LONG-ACTING LIPOSOMAL COMPOSITION FOR TREATMENT OF PAIN IN ARTICULAR DISORDERSDecember 2024September 2025Allow920YesNo
18978002GUM-PROTECTING AND TEETH-WHITENING STRIP AND PREPARATION METHOD THEREOFDecember 2024May 2025Allow520NoNo
18957404MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESNovember 2024April 2025Allow510YesNo
18951096Lip Balm Containing Caffeine, Nicotine or TestosteroneNovember 2024March 2025Allow410NoNo
18947765THERAPEUTIC PUTTIES CONTAINING ADDITIVES INCLUDING PROCESSED HUMAN BLOOD PLASMANovember 2024March 2026Allow1610NoNo
18864569TRIPTOLIDE LIGNOCERATE, LIPOSOME THEREOF AND PREPARATION METHOD THEREFORNovember 2024January 2026Allow1421NoNo
18940508METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONSNovember 2024January 2026Allow1410NoNo
18928808TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHOSPHOLIPIDSOctober 2024October 2025Allow1200NoNo
18929552DUAL MATERIAL IMPLANTOctober 2024October 2025Allow1200NoNo
18922818MEDICAL MATERIALOctober 2024July 2025Allow911YesNo
18920828MEDICAL DEVICES CONTAINING COMPOSITIONS OF POLY(BUTYLENE SUCCINATE) AND COPOLYMERS THEREOFOctober 2024October 2025Allow1200NoNo
18912716LIPID NANOPARTICLESOctober 2024July 2025Allow911NoNo
18908438ARTESUNATE POWDERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MANUFACTUREOctober 2024May 2025Allow711YesNo
18906740METHOD OF DELIVERY OF DNA OR RNA CARGO USING UNSHIELDED LIPID NANOPARTICLES AND COMPOSITIONS THEREOFOctober 2024March 2025Allow510NoNo
18848678BIOACTIVE GRANULAR HYDROGEL SCAFFOLDS AND USE THEREOFSeptember 2024April 2025Allow720YesNo
18886244Oral Care Compositions Comprising Monodentate And Polydentate LigandSeptember 2024June 2025Allow920YesNo
18830292HYDROPHOBIC ORAL CARE COMPOSITIONS WITH HYDROPHOBIC HERBAL EXTRACTSeptember 2024September 2025Allow1220NoNo
18825766LARGE-SCALE MANUFACTURING METHODS FOR AMINOGLYCOSIDESSeptember 2024September 2025Allow1321YesNo
18842405ORAL CARE PRODUCTAugust 2024February 2025Allow500NoNo
18833679ANTIBODY-BOUND LIPID NANOPARTICLE COMPRISING ANTIBODY BOUND TO MEMBRANE SCAFFOLD PROTEINAugust 2024July 2025Allow1110YesNo
18808392TREATMENT OF IMMUNOSUPPRESSED SUBJECTSAugust 2024March 2025Allow710NoNo
18806627Technology for improving properties of lipid nanoparticles using lipids in which cis-unsaturated bonds are substiuted with a silicon atomAugust 2024March 2025Allow710NoNo
18784316SUNSCREEN COMPOSITION AND METHODS OF PROTECTION FROM ULTRAVIOLET AND VISIBLE LIGHTJuly 2024January 2026Allow1810NoNo
18782666ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONSJuly 2024February 2025Allow610YesNo
18783305HYDROGEL FORMULATIONS AND METHODS AND DEVICES FOR ADMINISTRATION OF THE SAMEJuly 2024December 2024Allow500NoNo
18781300LIP BALM CONTAINING CAFFEINE, NICOTINE OR TESTOSTERONEJuly 2024August 2024Allow100NoNo
18781282LIP BALM CONTAINING CAFFEINE, NICOTINE OR TESTOSTERONEJuly 2024August 2024Allow100NoNo
18777142PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USEJuly 2024February 2026Abandon1901NoNo
18775688COMPOSITION & METHODS FOR REGULATING MELANOGENESISJuly 2024October 2024Allow300NoNo
18769488GUM AND TOOTH TREATMENT METHOD WITH RINSINGJuly 2024October 2024Allow310NoNo
18768689LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOFJuly 2024March 2025Allow910NoNo
18765624Fenugreek Formulation for Lowering Blood Glucose and Weight LossJuly 2024February 2025Allow711NoNo
18763543BIODEGRADABLE NANOCOMPOSITE SURGICAL SCREW CONTAINING BONE NANOPARTICLESJuly 2024May 2025Allow1001YesNo
18762795MANGANESE-DOPED HOLLOW MESOPOROUS SILICA NANOPARTICLES LOADED WITH CURCUMINJuly 2024November 2024Allow510NoNo
18762013MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024February 2025Allow820NoNo
18762242PROCESS OF PREPARING MRNA-LOADED LIPID NANO PARTICLESJuly 2024January 2026Allow1820NoNo
18761863MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024October 2024Allow311YesNo
18761882MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024November 2024Allow511YesNo
18761235STRUCTURALLY DIVERSE, STABLE, AND RADIATION-PROTECTIVE PARTICLE MATRIX SUNSCREEN AND COSMETIC COMPOSITIONS AND RELATED METHODSJuly 2024June 2025Allow1210NoNo
18759278COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTIONJune 2024May 2025Allow1110YesNo
18759260COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTIONJune 2024May 2025Allow1110YesNo
18757012HYPERTONIC ANTIMICROBIAL THERAPEUTIC COMPOSITIONSJune 2024August 2025Allow1310NoNo
18751924TRANSDERMAL SOLVENT SYSTEM AND METHODS OF USEJune 2024September 2025Abandon1510NoNo
18718353SUPRAMOLECULAR HYDROGEL FOR LIPOPHILIC DRUG DELIVERY, A PREPARATION METHOD THEREFOR, AND USE THEREOFJune 2024March 2025Allow910NoNo
18736363NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICSJune 2024April 2025Allow1010NoNo
18733977SINGLE DOSE ORAL HYGIENE UNIT OF TOOTHPASTE COMPOSITION AND METHOD OF MANUFACTUREJune 2024September 2025Abandon1521NoNo
18732903Oral Care CompositionsJune 2024November 2025Allow1720NoNo
18676591Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinMay 2024April 2025Abandon1110NoNo
18674445PHARMACEUTICAL FORMULATIONMay 2024September 2024Allow410NoNo
18672534DRUG DELIVERY SYSTEMS CONTAINING OXIDIZED CHOLESTEROLSMay 2024September 2025Abandon1510NoNo
18712146SKIN MIMICRY COMPOSITIONS AND IMPLANTSMay 2024March 2026Allow2200NoNo
18662516METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONSMay 2024April 2025Allow1110NoNo
186555714,4'-[(2-HYDROXYPROPANE-1,3-DIYL)BIS(OXY)]DIBENZALDEHYDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)May 2024October 2024Allow601NoNo
18651753PEST CONTROL SPRAYMay 2024February 2025Allow1010NoNo
18651036STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEApril 2024August 2024Allow410NoNo
18651026STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEApril 2024August 2024Allow310NoNo
18651154METHODS FOR DECREASING INJURIES ASSOCIATED WITH INTRAOPERATIVE HYPOTENSIONApril 2024November 2025Allow1820YesYes
18647232MICROBIAL INOCULANT COMPOSITIONS AND METHODSApril 2024October 2025Abandon1810NoNo
18636721Atomic Scale Topical Composition with Enhanced Interstitial Cellular Uptake for Increased Moisturizing, Fluidity, Antioxidant and Radiation Protection, Antimicrobial Cleansing and Therapeutics for Optimal Dermal Integrity and Homeostasis.April 2024November 2024Allow721YesNo
18633053Toothpaste for Delivery of Allergens to Oral MucosaApril 2024August 2025Allow1610NoNo
18631293POLYMER-ENCAPSULATED DRUG PARTICLESApril 2024January 2026Allow2110NoNo
18632083TREATMENT OF HEMATOLOGICAL DISORDERSApril 2024February 2026Allow2220NoNo
18630377PRESERVATIVE SYSTEMSApril 2024November 2025Allow1910NoNo
18699754TOOTHPASTE UTILIZING ROCHELLE SALT (SEGNETTE SALT) AS ABRASIVEApril 2024February 2026Allow2200NoNo
18625971Functional Porous Particles Embedded/Immobilized Within Porous Structures, Formation & Uses ThereofApril 2024August 2025Abandon1610NoNo
18619502COCHLEATES MADE WITH SOY PHOSPHATIDYLSERINEMarch 2024May 2025Allow1310NoNo
18620289METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYSMarch 2024January 2026Allow2200NoNo
18619103Application of AuCs or Substances Containing AuCs in the Preparation of Drugs for Preventing and/or Treating GlaucomaMarch 2024April 2025Allow1210NoNo
18694772COMPOSITION FOR REMEDYING INGROWN (TOE)NAILMarch 2024February 2026Allow2300NoNo
18613609Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal IrinotecanMarch 2024November 2025Abandon2040YesNo
18614050Core Shell Silica Particles and Use for Malodor ReductionMarch 2024March 2025Allow1210NoNo
18611735NANO LIQUID COMPOSITION CONTAINING CURCUMIN HAVE THE ABILITY TO TREATING BURNS AND INCREASING THE EFFECT OF SCAR HEALING AND METHOD OF MANUFACTURING THE SAMEMarch 2024July 2024Allow410NoNo
18608182LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOFMarch 2024September 2024Allow610NoNo
18608522OPHTHALMIC FORMULATIONMarch 2024July 2025Abandon1610NoNo
18607029CANCER THERAPY COMPOSITIONS AND USES THEREOFMarch 2024August 2025Allow1731NoNo
18604319Trans-Epithelial Membrane Drug Delivery SystemMarch 2024December 2024Allow910NoNo
18602863ORAL HYGIENE COMPOSITIONS AND METHODS OF USEMarch 2024March 2025Allow1210NoNo
18600658TREATMENT METHOD FOR TEETH AND GUMSMarch 2024May 2024Allow300NoNo
18594618COMPOSITION CONTROLLING PHARMACOKINETICS IN THE BODYMarch 2024November 2025Allow2101NoNo
18590455PROGAMMABLE POLYMERIC DRUGSFebruary 2024February 2026Allow2320NoNo
18589567Foaming Oral Care CompositionsFebruary 2024September 2025Allow1820NoNo
18586163ORAL HYGIENE COMPOSITIONS AND METHODS OF USEFebruary 2024August 2024Allow510YesNo
18583453GREEN SYNTHESIS OF SILVER NANOPARTICLES ENCAPSULATED IN A NANOSTRUCTURED LIPID CARRIERFebruary 2024September 2024Allow711YesNo
18444424SUNSCREEN FORMULATIONS AND METHODS OF MAKING AND USING THE SAMEFebruary 2024April 2025Allow1420YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1612.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
587
Examiner Affirmed
430
(73.3%)
Examiner Reversed
157
(26.7%)
Reversal Percentile
20.4%
Lower than average

What This Means

With a 26.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
2043
Allowed After Appeal Filing
419
(20.5%)
Not Allowed After Appeal Filing
1624
(79.5%)
Filing Benefit Percentile
8.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1612 - Prosecution Statistics Summary

Executive Summary

Art Unit 1612 is part of Group 1610 in Technology Center 1600. This art unit has examined 13,765 patent applications in our dataset, with an overall allowance rate of 48.0%. Applications typically reach final disposition in approximately 36 months.

Comparative Analysis

Art Unit 1612's allowance rate of 48.0% places it in the 7% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1612 receive an average of 2.45 office actions before reaching final disposition (in the 85% percentile). The median prosecution time is 36 months (in the 25% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.